Bajusz S, Fauszt I, Németh K, Barabás E, Juhász A, Patthy M, Bauer P I
Institute for Drug Research, Budapest, Hungary.
Biopolymers. 1999;51(1):109-18. doi: 10.1002/(SICI)1097-0282(1999)51:1<109::AID-BIP12>3.0.CO;2-S.
Interleukin-1 beta (IL-1 beta)-converting enzyme (ICE, caspase-1) processes the IL-1 beta precursor to mature inflammatory cytokine IL-1 beta. ICE has been identified as a unique cysteine protease, which cleaves Asp-X bonds, shows resistance to E-64 (an inhibitor of most cysteine proteases) and has a primary structure that is homologous to CED-3, a protein required for apoptosis (programmed cell death) in the nematode Caenorhabditis elegans, and to mammalian cysteine proteases that initiate and execute apoptosis, e.g., apopain/CPP32/caspase-3. The inhibitors of the ICE/CED-3 family or caspases, as they are called recently, may constitute therapeutic agents for amelioration of inflammatory and apoptosis-associated diseases. The most efficient ICE inhibitors are peptide aldehydes and peptidyl chloro or (acyloxy)methanes. A recent study revealed that both D- and L-Asp are accepted by ICE at the P1 of such inhibitors, and the peptidyl (acyloxy)methane analogues having the beta-homo-aspartyl residue [-NH-CH(CH2COOH)-CH2CO-] are inactive. These findings we reexamined in terms of two issues. (a) ICE's resistance to E-64. Since it was thought to be caused by the enzyme's unique substrate specificity, we prepared substrate-based analogues, which were not inhibitory suggesting significant structural difference between the active centers of ICE and papain-like enzymes. (b) Tolerance for D-stereochemistry at the P1 of these inhibitors. In view of the mechanism of cysteine protease inhibition by peptidyl X-methanes, we thought that this phenomenon should be a general characteristic of cysteine proteases and the hAsp-containing analogues should behave as reversible inhibitors. Here, we analyzed the inhibition of ICE and apopain in comparison with that of papain, thrombin, and trypsin by peptide L/D-alpha-aldehydes and their L-beta-homo-aldehyde [-NH-CH(R)-CH2-CHO] analogues. The following results were found. (1) The peptidyl L-beta-homo-aspartals are potent inhibitors for caspases. (2) The L-beta-homo analogues of peptide aldehyde inhibitors designed for other proteases are not inhibitory. (3) Unlike trypsin and thrombin (serine proteases), papain (cysteine protease) shows tolerance for D-stereochemistry at the P1 site of peptide aldehydes in proportion to the lability of the alpha-hydrogen of the P1-D-residue. The complete tolerance of ICE for P1-D-Asp may arise from this residue's high tendency to epimerization. (4) Reaction of cysteine proteases with peptide aldehyde or peptidyl X-methane inhibitors containing P1-D-residues may include alpha-proton abstraction followed by asymmetric induction leading to P1-L-residue-containing products.
白细胞介素-1β(IL-1β)转化酶(ICE,半胱天冬酶-1)将IL-1β前体加工成成熟的炎性细胞因子IL-1β。ICE已被鉴定为一种独特的半胱氨酸蛋白酶,它能切割天冬氨酸-X键,对E-64(大多数半胱氨酸蛋白酶的抑制剂)具有抗性,其一级结构与CED-3同源,CED-3是秀丽隐杆线虫中凋亡(程序性细胞死亡)所需的一种蛋白质,也与启动和执行凋亡的哺乳动物半胱氨酸蛋白酶同源,例如凋亡蛋白酶/CPP32/半胱天冬酶-3。ICE/CED-3家族的抑制剂,即最近所称的半胱天冬酶,可能构成用于改善炎症和凋亡相关疾病的治疗药物。最有效的ICE抑制剂是肽醛以及肽基氯或(酰氧基)甲烷。最近的一项研究表明,在这类抑制剂的P1位点,D-天冬氨酸和L-天冬氨酸都能被ICE接受,而具有β-高天冬氨酰残基[-NH-CH(CH2COOH)-CH2CO-]的肽基(酰氧基)甲烷类似物没有活性。我们从两个问题的角度重新审视了这些发现。(a)ICE对E-64的抗性。由于认为这是由该酶独特的底物特异性引起的,我们制备了基于底物的类似物,它们没有抑制作用,这表明ICE和木瓜蛋白酶样酶的活性中心之间存在显著的结构差异。(b)这些抑制剂在P1位点对D-立体化学的耐受性。鉴于肽基X-甲烷对半胱氨酸蛋白酶的抑制机制,我们认为这种现象应该是半胱氨酸蛋白酶的一个普遍特征,而含hAsp的类似物应该表现为可逆抑制剂。在这里,我们通过肽L/D-α-醛及其L-β-高醛[-NH-CH(R)-CH2-CHO]类似物,分析了ICE和凋亡蛋白酶与木瓜蛋白酶、凝血酶和胰蛋白酶相比的抑制情况。发现了以下结果。(1)肽基L-β-高天冬氨醛是半胱天冬酶的有效抑制剂。(2)为其他蛋白酶设计的肽醛抑制剂的L-β-高类似物没有抑制作用。(3)与胰蛋白酶和凝血酶(丝氨酸蛋白酶)不同,木瓜蛋白酶(半胱氨酸蛋白酶)对肽醛在P1位点的D-立体化学的耐受性与P1-D-残基的α-氢的不稳定性成比例。ICE对P1-D-天冬氨酸的完全耐受性可能源于该残基的高差向异构化倾向。(4)半胱氨酸蛋白酶与含有P1-D-残基的肽醛或肽基X-甲烷抑制剂的反应可能包括α-质子提取,随后是不对称诱导,导致形成含P1-L-残基的产物。